Preclinical and First-in-Human Study of a Compact Radionuclide Labeled Self-Assembly Nanomedicine for Chemo-Radio-Theranostics of Cancer
- 13 January 2025
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (3) , 3953-3965
Abstract
The emerging combination of chemotherapy and radionuclide therapy has been actively investigated to overcome the limitations of monotherapy and augment therapeutic efficacy. However, it remains a challenge to design a single delivery vehicle that can incorporate chemotherapeutics and radionuclides into a compact structure. Here, a chelator DOTA- or NOTA-modified Evans blue conjugated camptothecin molecule (EB-CPT) nanoprodrug was synthesized, which could self-assemble into nanoparticles due to its inherent amphiphilicity. The nanoparticles could then be effectively labeled with therapeutic radionuclide lutetium-177 (177Lu) or diagnostic radionuclides gallium-68 (68Ga)/copper-64 (64Cu) with high radiolabeling efficiency and radiochemical stability. Impressively, a single-dose chemoradiation therapy of [177Lu]Lu-DOTA-EB-CPT plus EB-CPT effectively inhibited tumor growth in HCT116 tumor-bearing mice compared to the respective individual therapeutic approach. The [64Cu]Cu-NOTA-EB-CPT nanoparticles also exhibited excellent in vivo characteristics including favorable blood circulation properties and prolonged tumor retention in tumor-bearing mice. The safety, feasibility, tolerability, and biodistribution of [68Ga]Ga-NOTA-EB-ss-CPT were also preliminarily characterized in a first-in-human study. This study presents a simple but robust EB-CPT radiopharmaceutical that leverages EB as an albumin binder to strike a delicate balance between enhanced tumor accumulation, safety, and diagnostic efficacy, facilitating an integrated theranostic strategy within a single molecular structure. This radionuclide-labeled EB-CPT nanomedicine presents a step toward clinical translation of the combination of chemotherapy and radiotheranostics.Keywords
Funding Information
- National Medical Research Council (CG21APR1005, MOH-001254-01, MOH-001334-00, MOH-001388-00)
- Ministry of Education - Singapore (FY2022, MOE-000387-00)
- China Postdoctoral Science Foundation (2022M722654)
- Natural Science Foundation of Fujian Province (2023J06007)
- National Research Foundation Singapore (NRF-000352-00)
- Science, Technology and Innovation Commission of Shenzhen Municipality (JCYJ20220530143400001)
- National University of Singapore (NUHSRO/2020/133/Startup/08, NUHSRO/2021/034/TRP/09/Nanomedicine, NUHSRO/2021/097/Startup/13, NUHSRO/2022/093/T1/Seed-Sep/06, NUHSRO/2023/008/NUSMed/TCE/LOA)
- National Natural Science Foundation of China (82272136)
- Xiamen University (X2123305)
- Fujian Province (2021L3001)
This publication has 37 references indexed in Scilit:
- Microenvironmentally Responsive Chemotherapeutic Prodrugs and CHEK2 Inhibitors Self‐Assembled Micelles: Protecting Fertility and Enhancing ChemotherapyAdvanced Materials, 2023
- The effects of protein corona on in vivo fate of nanocarriersAdvanced Drug Delivery Reviews, 2022
- Exquisite Vesicular Nanomedicine by Paclitaxel Mediated Co‐assembly with Camptothecin ProdrugAngewandte Chemie International Edition, 2021
- Pure redox-sensitive paclitaxel–maleimide prodrug nanoparticles: Endogenous albumin-induced size switching and improved antitumor efficiencyActa Pharmaceutica Sinica B, 2021
- Macrocyclic‐Amphiphile‐Based Self‐Assembled Nanoparticles for Ratiometric Delivery of Therapeutic Combinations to TumorsAdvanced Materials, 2021
- Diagnosis and Treatment of Metastatic Colorectal CancerJAMA, 2021
- Targeted melanoma radiotherapy using ultrasmall 177Lu-labeled α-melanocyte stimulating hormone-functionalized core-shell silica nanoparticlesBiomaterials, 2020
- Self‐Assembly of an Amphiphilic Janus Camptothecin–Floxuridine Conjugate into Liposome‐Like Nanocapsules for More Efficacious Combination Chemotherapy in CancerAdvanced Materials, 2017
- Opportunities and challenges in combination gene cancer therapyAdvanced Drug Delivery Reviews, 2016
- Targeted drug delivery to tumors: Myths, reality and possibilityJournal of Controlled Release, 2011